Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer.
The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer.
The FDA granted a priority review to Deciphera Pharmaceuticals’ new drug application for ripretinib to treat patients with advanced gastrointestinal stromal tumors.
Bristol-Meyers Squibb Company announced that the FDA granted a priority review to its BLA for liso-cel to treat patients with relapsed or refractory large B-cell lymphoma.
A recent study determined circulating tumor cells were associated with melanoma relapse, suggesting that this form of liquid biopsy could help identify patients who would benefit from adjuvant therapy.
Janssen Pharmaceutical Companies submitted a supplemental biologics license application for daratumumab in combination with carfilzomib and dexamethasone to treat patients with relapsed/refractory multiple myeloma.
The FDA granted a priority review to capmatinib, a MET inhibitor being analyzed for the first-line treatment of previously treated patients with METex14-mutated advanced NSCLC.
A recent study found that patients with stage III breast cancer did not benefit from high-dose chemotherapy, nor did it impact long-term risks of major cardiovascular events.
Calibr received approval from the FDA to move forward with an investigational new drug to treat relapsed/refractory B-cell malignancies with a switchable CAR T-cell therapy.
A recent study suggests older women with estrogen receptor-positive, clinically node-negative, early-stage breast cancer can omit axillary surgery, while nodal positivity declines with advancing age.